On this page:Overview Publications Researchers Key papers Journals Open access Institutions

ScholarIQanswers from OpenAlex

Prostate Cancer Treatment and Research

TopicLeading institutions, researchers & key papers

Prostate Cancer Treatment and Research is a topic indexed in ScholarIQ from OpenAlex.

What is known about Prostate Cancer Treatment and Research?

ScholarIQrecord summary

This cluster of papers represents a comprehensive exploration of advancements in prostate cancer research, covering topics such as androgen receptor signaling, genomic profiling, hormone therapy, immunotherapy, genetic mutations, clinical trials, biomarkers, and molecular biology. The papers discuss the molecular determinants of resistance to antiandrogen therapy, the impact of translocations and gene fusions on cancer causation, and the development of second-generation antiandrogens for the treatment of advanced prostate cancer.

How many works does Prostate Cancer Treatment and Research have?

ScholarIQindexed works

Prostate Cancer Treatment and Research has 414 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Prostate Cancer Treatment and Research →

What is the OpenAlex record for Prostate Cancer Treatment and Research?

ScholarIQopenalex

The OpenAlex for Prostate Cancer Treatment and Research is on the source record.

Open the OpenAlex →

What are the most-cited papers on Prostate Cancer Treatment and Research?

ScholarIQmost cited works

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Ian F. Tannock, Ronald de Wit, William R. Berry, J Horti, A Płużańska, Kim N., Stéphane Oudard, Christine Théodore, Nicholas D. James, Ingela Turesson, Mark Rosenthal, Mario A. Eisenberger

New England Journal of Medicine. 20045,744 Citations

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono

New England Journal of Medicine. 20124,604 CitationsOPEN ACCESS

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher

New England Journal of Medicine. 20114,422 CitationsOPEN ACCESS

Integrative Genomic Profiling of Human Prostate Cancer

Barry S. Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao, Brett S. Carver, Vivek Arora, Poorvi Kaushik, Ethan Cerami, Boris Reva, Yevgeniy Antipin, Nicholas Mitsiades, Thomas Landers, Igor Dolgalev, John E. Major, Manda Wilson, Nicholas D. Socci, Alex Lash, Adriana Heguy, James A. Eastham, Howard I. Scher, Victor E. Reuter, Peter T. Scardino, Chris Sander, Charles L. Sawyers, William L. Gerald

Cancer Cell. 20103,815 CitationsOPEN ACCESS

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford

New England Journal of Medicine. 20043,691 CitationsOPEN ACCESS

Where is Prostate Cancer Treatment and Research research published, and who funds it?

ScholarIQvenues & funding sources

TOP JOURNALS

New England Journal of Medicine37,177

Cell6,960

Cancer Cell3,815

The Lancet3,299

TOP FUNDERS

National Science Foundation—

NIH—

Wellcome Trust—

European Research Council—

Funder breakdown is a member featureSign up free to unlock

How much of the research on Prostate Cancer Treatment and Research is open access?

ScholarIQopen access share

87%OPEN ACCESS

Gold

Green

Hybrid

Bronze

73%

Closed

13%